Alanine News and Research

RSS

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Saffron promotes apoptosis and inhibits growth of cancerous cells

New research suggests that saffron provides a significant chemopreventive effect against liver cancer in animal models. When saffron was administered to rats with diethylnitrosamine (DEN)-induced liver cancer an inhibition of cell proliferation and stimulation of apoptosis was observed. Full findings appear in the September issue of Hepatology, a journal published by Wiley Blackwell on behalf of the American Association for the Study of Liver Diseases.

22 Aug 2011

NAI reaches settlement with VPX over beta-alanine patent litigation

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S. District Court for the District of Delaware, Vital Pharmaceutical, Inc..

12 Aug 2011

New insight into tumor biology

Cancer cells are well known for their altered metabolisms, which may help them generate the energy they need for rapid growth. Using an emerging imaging technology, researchers reporting in the July Cell Metabolism, a Cell Press publication, have discovered that those metabolic shifts actually develop even before detectable tumors form.

6 Jul 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Vitamin E effective against severe fatty liver disease in some children

A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease.

28 Apr 2011

Children, adolescents with liver disease may not benefit from vitamin E or metformin

In contrast to previous preliminary data, use of vitamin E or the diabetes drug metformin was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents, according to a study in the April 27 issue of JAMA.

27 Apr 2011

Research sheds light on molecular movements of neural transporters

A team of scientists from Columbia University College of Physicians and Surgeons and Weill Cornell Medical College has shed light on the molecular workings of transporter proteins, molecular machines embedded in the cell membranes of neurons that modulate the transfer of signals between cells and recycle neurotransmitters.

25 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

Football player announces release of new pre-workout intensity supplement

Ray Lewis, one of the greatest players ever to step on a football field, today announced the release of an all new pre-workout intensity supplement, called Power Fuel, which will feature Lewis on its packaging and contain a powerful custom ingredient blend named in his honor.

5 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011